Privacy

Cookie Policy

Contact

Home

ABOUT

Editorial

PRESS RELEASES

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR

SUBSCRIBE

Market Reports

FDA

Executives

Funding

Non Profits

Hospitals

Acquisitions

Health

Biotechnology News Magazine

HomeEXECUTIVESAdam S. Epstein New CEO of AliMed, Inc.

Adam S. Epstein New CEO of AliMed, Inc.

Healthcare product manufacturer and distributor, AliMed, Inc. announced today the promotion of Adam S. Epstein, 51, to the position of Chief Executive Officer, effective immediately. In his new role, Adam S. Epstein will oversee the company’s general operations and its diversified portfolio of products sold to a majority of the country’s leading healthcare providers.

In his prior role as Chief Commercial Officer, Epstein directed all customer-facing, demand generation and product development activities. Under his new leadership, AliMed will continue to build a robust portfolio of contracted positions with major, national GPO’s, IDN’s, and Distribution partners to drive sales growth. The company has also reinvested in product development and has a strong pipeline of new products now commercializing for use in both acute and post-acute care settings.

AliMed’s strong brand identity is synonymous with 50-years of innovative products and customizations developed to address a range of healthcare challenges. “Adam has done a great job strengthening our relationships with major customers and key sales partners,” said AliMed’s Chair of the Board and President, Alexandra Cherubini. “He is committed to remaining relevant to our key partners and inspiring customer loyalty to our brand. He is a tremendous leader and I’m confident he will guide our business to even greater success.”

Epstein has worked at AliMed since late 2019. Prior to that, he held senior roles at UFP Technologies (NASDAQ: UFPT) and Dielectrics, Inc. leading the development, commercialization, and sales of medical products and devices.

“I am excited about continuing to build the business with our talented and dedicated team of professionals,” Epstein said. “The important work AliMed does, enables caregivers to positively impact their patients’ lives. Our mission is helping people help people. We’re proud to be doing that on many fronts, through our broad product portfolio, signature service, and community engagement program, AliCares.” Epstein holds degrees from the University of Rochester and the Isenberg School of Management at UMASS.

AliMed Inc. headquartered in Dedham, MA and founded over 50 years ago by Barbara and Julian Cherubini, built its reputation on high-value, differentiated offerings and exceptional service. This specialty medical supplies manufacturer and distributor has on-site customization capabilities for both domestic and international care providers, dealers, and distributors. AliMed’s broad portfolio of healthcare products is designed to improve patient outcomes and experience, serving needs from “hospital to home”.

spot_img

DON'T MISS

United States Cardiovascular Devices Market 2021-2027

United States Cardiovascular Devices Market is projected to reach US$ 39.98 Billion by 2027 from US$ 25.34 Billion in 2020, growing with a CAGR of 6.73%

Global Cerebrospinal Fluid Drainage Catheter Market (2021 to 2027) – by Application, Type and Regional Outlook

The Global Cerebrospinal Fluid Drainage Catheter Market size is expected to reach $402.6 Million by 2027, rising at a market growth of 8.6% CAGR during the forecast period. For the treatment of hydrocephalus, placement of cerebral spinal fluid (CSF) shunt systems is becoming a common medical and life-saving procedure for the majority of the patients.

United States Insulin Delivery Devices Market Report 2021

This new report provides an in-depth assessment of the U.S insulin delivery devices market dynamics, opportunities, future road-map, competitive landscape and discusses major trends.

Global $45 Billion Endoscopy Market Insights & Forecasts to 2025

The global endoscopy market is predicted to reach US$45.28 billion in 2025, growing, at a CAGR of 7.50%, for the duration spanning 2021-2025.

Our Sister Publication: Biotechnology News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy